Free Trial
NASDAQ:AIKI

AIkido Pharma (AIKI) Stock Price, News & Analysis

AIkido Pharma logo
$1.26 -0.05 (-3.89%)
(As of 12/20/2024 ET)

About AIkido Pharma Stock (NASDAQ:AIKI)

Key Stats

Today's Range
$1.24
$1.31
50-Day Range
$1.31
$3.56
52-Week Range
$3.31
$11.48
Volume
14,150 shs
Average Volume
79,326 shs
Market Capitalization
$6.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

AIKI Stock News Headlines

SNOA Sonoma Pharmaceuticals, Inc.
Royalty Pharma PLC
2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis
Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.
Dominari Holdings Inc. Releases Shareholder Update
Kyle Wool Appears on Fox Business
Dominari Holdings Appoints George Way As CFO
See More Headlines

AIKI Stock Analysis - Frequently Asked Questions

AIkido Pharma's stock was trading at $2.59 at the beginning of the year. Since then, AIKI stock has decreased by 51.4% and is now trading at $1.26.
View the best growth stocks for 2024 here
.

AIkido Pharma shares reverse split on the morning of Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

AIkido Pharma subsidiaries include these companies: Hoth Therapeutics.

Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that AIkido Pharma investors own include Atossa Therapeutics (ATOS), iBio (IBIO), Bionano Genomics (BNGO), Ocugen (OCGN), Meta Platforms (META), Cineverse (CNVS) and

Company Calendar

Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:AIKI
Employees
4
Year Founded
1967

Profitability

Net Income
$-7,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$19.27 per share

Miscellaneous

Free Float
5,013,000
Market Cap
$6.91 million
Optionable
Not Optionable
Beta
0.93

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:AIKI) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners